Microenvironmental Trial of Classical Hodgkin Lymphoma in Adolescents

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06814860

Acronym

LH2004ME

Enrollment

Registered

2025-02-07

Start date

2024-02-07

Completion date

2024-10-31

Last updated

2025-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Classical Hodgkin Lymphoma

Keywords

Hodgkin Lymphoma, adolescent, microenvironment, immune-check points

Brief summary

Background. Classical Hodgkin's lymphoma (cHL) in adolescents between 15 and 18 years shows a higher disease-related mortality and the overall prognosis is worse than both children and adults. Objectives. To investigate the immune checkpoint inhibitors (ICPI) therapeutic targets and specific T-regulatory and cytotoxic T-cell subsets, in the subgroup of adolescent cHL patients and to investigate their prognostic power. Methods: Retrieved formalin-fixed paraffin-embedded (FFPE) of adolescent patients diagnosed with cHL with available clinical and tested by immunohistochemistry the immune checkpoint molecules CTLA-4, LAG-3, PD-1 and PDL1 and the biological markers FOXP3 and CD8.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

12 Years to 18 Years

Healthy volunteers

Inclusion criteria

* Patients aged 12 to 18 years at diagnosis of Classical Hodgkin lymphoma.

Exclusion criteria

* Unavailability/insufficiency of histological material for diagnosis.

Design outcomes

Primary

Measure	Time frame	Description
Characterization of the tumour microenvironment	through study completion, an average of 3 months	Identification of phenotypic markers with possible prognostic and/or therapeutic impact predictive of clinical outcomes in patients undergoing LHC in pediatric/adolescent age.

Countries

Italy

Outcome results